Cost & Insurance

Medicare GLP-1 Bridge Program: What It Is and How to Access It in 2026

GLP-1 Companion · 8 min read

If you have been searching for "Medicare GLP-1 bridge program," you are likely in one of these situations: your Part D plan does not cover your GLP-1 medication, you are in the coverage gap (historically called the "donut hole"), or you are transitioning between insurance plans and need to maintain access during the gap. A bridge program is a temporary pathway — provided by a manufacturer, a pharmacy assistance program, or a clinical arrangement — to keep patients on medication while insurance issues are resolved.

Does Medicare Cover GLP-1 Medications for Weight Loss?

This is the most important context to establish. As of 2026, standard Medicare Part D plans cover GLP-1 medications when they are prescribed for type 2 diabetes (Ozempic, Rybelsus, Mounjaro in its diabetes indication). Coverage for GLP-1 drugs prescribed specifically for weight management — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide for obesity), and Saxenda — has historically been excluded by Medicare under the law that bans Part D coverage of "drugs used for anorexia, weight loss, or weight gain."

The Treat and Reduce Obesity Act (TROA), which would change this prohibition, has been introduced in multiple Congressional sessions. As of mid-2026, coverage expansion under Medicare remains under active legislative debate. Some Medicare Advantage plans have begun offering supplemental GLP-1 obesity coverage as an extra benefit, but this varies widely by plan and region. Check your specific Medicare Advantage plan's drug formulary for the most current status.

What Is a Bridge Program for GLP-1 Medications?

A "bridge program" for GLP-1 medications is any arrangement that provides short-term access — usually free or reduced-cost medication — to patients who temporarily lack insurance coverage or who are waiting for prior authorization to be approved. The term is used informally to describe several different types of programs:

• Manufacturer Patient Assistance Programs (PAPs): Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) both offer patient assistance programs for uninsured or underinsured patients who meet income requirements.
• Manufacturer Bridge Supplies: When a patient's prior authorization is pending or an appeal is in process, some manufacturers will provide a short supply (typically 1–3 months) of medication at no charge to prevent interruption.
• Prescription Savings Coupons and Cards: NovoCare, Lilly Cares, and third-party platforms like GoodRx may reduce out-of-pocket costs significantly for commercially insured patients — but usually do not apply to Medicare beneficiaries.
• Telehealth Compounding Bridge: Some telehealth providers offer compounded semaglutide or tirzepatide at lower cost while patients await insurance coverage (see important note below).

The Medicare Bridge Program: Is It a Formal Federal Program?

There is no single official federal program called the "Medicare GLP-1 Bridge Program." The term has emerged organically from patients and healthcare providers to describe the informal patchwork of solutions available when Medicare coverage falls short. When you see references to a "Medicare bridge program" online, they are almost always describing one of these non-federal options — primarily manufacturer patient assistance programs.

Some Medicare Advantage plans have created their own internal bridge supply programs for members whose GLP-1 prior authorizations are under appeal. If you have Medicare Advantage (not Original Medicare), call the number on the back of your insurance card and ask specifically whether your plan offers a bridge supply while an appeal is pending.

Novo Nordisk Patient Assistance: NovoCare Program

NovoCare is Novo Nordisk's patient support program for Ozempic, Wegovy, and Rybelsus. For patients who do not have insurance coverage or whose Medicare plan does not cover their medication, NovoCare offers free medication to those who meet income eligibility criteria. As of 2026, eligibility generally requires:

• US residency and a valid prescription from a licensed US provider
• Annual household income at or below 400% of the Federal Poverty Level (FPL) — roughly $60,000/year for a single person or $124,000 for a family of four in 2026
• No insurance coverage for the requested medication (Medicare Part D beneficiaries without obesity coverage typically qualify)
• Documentation of financial need

To apply, visit NovoCare.com or call 1-833-NOVO-411. Your prescribing provider will need to submit documentation on your behalf. Processing times vary but often take 2–4 weeks, which is why having a bridge supply request in place before your current supply runs out is important.

Lilly Cares Patient Assistance: Mounjaro and Zepbound

Eli Lilly's patient assistance program, Lilly Cares, provides free Mounjaro and Zepbound to eligible uninsured or underinsured patients. Income eligibility is similar to NovoCare — generally up to 400% FPL — and Medicare Part D patients without coverage for their specific obesity indication typically qualify.

Lilly also offers savings cards that reduce the cost of Zepbound to $550/month or less for commercially insured patients — but this card explicitly cannot be used by Medicare or Medicaid beneficiaries. For Medicare patients, Lilly Cares is the correct pathway. Visit LillyCares.com or call 1-800-545-5979 to begin an application.

Steps to Take If Your Medicare Coverage Is Interrupted

1. Contact your prescriber immediately. Your provider's office often has experience navigating coverage gaps and may know about local resources or existing bridge supply stock.
2. Request a prior authorization appeal if your medication was denied. Medicare rules require plans to respond to standard appeals within 60 days and expedited appeals within 72 hours. During this period, ask whether your plan provides a bridge supply.
3. Apply to the manufacturer's patient assistance program (NovoCare or Lilly Cares). Even if you have Medicare, you may qualify for free medication if your Part D plan does not cover the specific drug for your indication.
4. Ask about compounded alternatives cautiously. The FDA has classified semaglutide as no longer in shortage (as of May 2025), meaning compounded semaglutide from outsourcing facilities is not legally permitted as a routine bridge. Consult your prescriber before pursuing this route.
5. Contact your State Health Insurance Assistance Program (SHIP). SHIP counselors are free, unbiased advisors funded by Medicare who can help you understand your options and appeal rights. Find your local SHIP at shiphelp.org.

Extra Help and Low-Income Subsidy (LIS)

If your income is limited, you may qualify for Medicare's Extra Help program (also called the Low-Income Subsidy or LIS). Extra Help significantly reduces Part D premiums, deductibles, and copayments — including for diabetes medications like Ozempic and Mounjaro used for T2D. This is not a bridge program per se, but it may dramatically reduce or eliminate your out-of-pocket costs for covered GLP-1 medications. Apply through SSA.gov or your local Social Security office.

State Pharmaceutical Assistance Programs (SPAPs)

Several states operate their own pharmaceutical assistance programs for Medicare beneficiaries that supplement Part D coverage. States with active SPAPs that may help with GLP-1 costs include New Jersey (PAAD), Pennsylvania (PACE), New York (EPIC), and Connecticut (CONNPACE), among others. Eligibility and covered drugs vary by state. Your SHIP counselor can tell you whether your state has a relevant program.

Bottom Line

The "Medicare GLP-1 bridge program" most people are searching for is primarily the manufacturer patient assistance programs offered by Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares). These programs can provide free or low-cost GLP-1 medication to Medicare beneficiaries whose plans do not cover their prescribed drug. The process takes time, so it is critical to act before you run out of medication rather than after.

On the legislative front, the debate over expanding Medicare Part D coverage to obesity medications continues. If coverage expands under future legislation, the need for these bridge arrangements may diminish — but until then, knowing how to navigate manufacturer assistance programs is the most reliable path to maintaining access.